Earnings Summary

Adc Therapeutics Sa’s revenue fell -75.94% since last year same period to $16.79Mn in the Q4 2023. On a quarterly growth basis, Adc Therapeutics Sa has generated 15.85% jump in its revenue since last 3-months.

Adc Therapeutics Sa’s net profit fell -251.99% since last year same period to $-85.03Mn in the Q4 2023. On a quarterly growth basis, Adc Therapeutics Sa has generated -77.86% fall in its net profits since last 3-months.

Adc Therapeutics Sa’s net profit margin fell -1363.28% since last year same period to -506.44% in the Q4 2023. On a quarterly growth basis, Adc Therapeutics Sa has generated -53.53% fall in its net profit margins since last 3-months.

Adc Therapeutics Sa’s earning per share (EPS) estimates for the current quarter stand at -0.56 - a -12% fall from last quarter’s estimates.

Adc Therapeutics Sa’s earning per share (EPS) estimates for the current year stand at -0.56.

Adc Therapeutics Sa’s earning per share (EPS) fell -243.33% since last year same period to -1.03 in the Q4 2023. This indicates that the Adc Therapeutics Sa has generated -243.33% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Adc Therapeutics Sa’s return on assets (ROA) stands at -0.25.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Adc Therapeutics Sa’s return on equity (ROE) stands at -7.06.